Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza Tablets, 2.5 mg and 5 mg of AstraZeneca AB.
Onglyza Tablets, 2.5 mg and 5 mg achieved annual sales of around $518.5 million for the 12 month period ending April 2017.
The company’s current portfolio consists of 117 products authorized for distribution in the U.S. marketplace and 68 ANDA’s pending approval with the USFDA. In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1653.80 |
| Dr. Reddys Lab | 1215.95 |
| Cipla | 1228.20 |
| Zydus Lifesciences | 927.75 |
| Lupin | 2307.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: